Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia - Dimopoulos, Meletios A; Tedeschi, Alessandra; Trotman, Judith; García-Sanz, Ramón; Macdonald, David; Leblond, Veronique; Mahe, Beatrice; Herbaux, Charles; Tam, Constantine; Orsucci, Lorella; Palomba, M. Lia; Matous, Jeffrey V; et al. (The New England journal of medicine, 2018)
Keywords: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Arthralgia; Atrial Fibrillation - chemically induced; B-cell lymphoma; Bone marrow; Cancer; CXCR4 protein; Diarrhea; Disease-Free Survival; Female; Fibrillation; Hemoglobin; Hemoglobins - analysis; Hemorrhage; Hospitals; Humans; Hypertension; Immunoglobulin M; Immunoglobulin M - blood; Immunotherapy; Infusions, Intravenous - adverse effects; Inhibitor drugs; Lymphocytes B; Macroglobulinemia; Male; Medical research; Middle Aged; Monoclonal antibodies; MyD88 protein; Nausea; Patients; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; R&D; Research & development; Response rates; Rituximab; Rituximab - administration & dosage; Rituximab - adverse effects; Survival Analysis; Targeted cancer therapy; Waldenstrom Macroglobulinemia - blood; Waldenstrom Macroglobulinemia - drug therapy